This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cyclacel Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Cyclacel Pharmaceuticals has a total shareholder equity of $4.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $12.5M and $8.2M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$5.94m |
| Aandelen | US$4.30m |
| Totaal verplichtingen | US$8.20m |
| Totaal activa | US$12.50m |
Recente financiële gezondheidsupdates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: UXI's short term assets ($11.1M) exceed its short term liabilities ($8.1M).
Langlopende schulden: UXI's short term assets ($11.1M) exceed its long term liabilities ($52.0K).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: UXI is debt free.
Schuld verminderen: UXI has not had any debt for past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: UXI has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: UXI is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.